Metagenomi director granted options on 21,000 shares
Metagenomi Therapeutics director Dere Willard H received a grant of stock options covering 21,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Metagenomi Therapeutics director Dere Willard H received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. These options vest in full on the earlier of one year after the grant date or the company’s 2027 annual stockholder meeting, provided he continues serving the company through that vesting date.
Insider Trade Summary
Grant/Award: 21,000 shares
Grant/Award
1 txn
Insider
Dere Willard H
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 21,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 21,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Key Figures
Option grant size: 21,000 shares
Exercise price: $1.23 per share
Expiration date: June 8, 2036
+1 more
4 metrics
Option grant size
21,000 shares
Stock Option (Right to Buy) granted to director
Exercise price
$1.23 per share
Stock option strike price for underlying common stock
Expiration date
June 8, 2036
Option term end for the 21,000-share grant
Shares underlying options after grant
21,000 shares
Total derivative shares following this reported transaction
Key Terms
Stock Option (Right to Buy), exercise price, Grant Date, vest and become exercisable, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "1.2300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Grant Date financial
"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
vest and become exercisable financial
"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary"
annual meeting of stockholders financial
"or (ii) the date of the Company's 2027 annual meeting of stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Metagenomi Therapeutics (MGX) report for Dere Willard H?
Metagenomi Therapeutics reported that director Dere Willard H received a stock option grant for 21,000 shares. The award is compensation-based, not an open-market trade, and gives him the right to buy common stock at a fixed exercise price if vesting conditions are satisfied.
What is the exercise price and expiration date of the Metagenomi (MGX) option grant?
The stock options have an exercise price of $1.23 per share and expire on June 8, 2036. This means the director can, if vested, buy shares at $1.23 any time before that expiration date, regardless of the market price then.
When do Dere Willard H’s Metagenomi Therapeutics (MGX) options vest?
The options vest and become exercisable on the earlier of one year after the grant date or the company’s 2027 annual stockholder meeting. Vesting is conditional on Dere Willard H continuing his service with Metagenomi Therapeutics through that vesting date, according to the footnote disclosure.
Is Dere Willard H’s Metagenomi (MGX) Form 4 transaction a market purchase or sale?
The Form 4 shows a grant of stock options, not a market purchase or sale. It is coded as a grant or award acquisition, meaning the director received options as compensation rather than buying or selling common shares in the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates